Krishna Gorti

Analysts at Piper Jaffray reiterated their underweight rating for Cytori Therapeutics (NASDAQ: CYTX) on news that Cytori’s Celution system launch will be delayed. Analysts at Piper Jaffray noted that “shares of CYTX are down 36% over the last four trading sessions since Cytori reported that the FDA...